MGX · XBRL financial data
Metagenomi Therapeutics financial statements, every fiscal year
The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MGX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | 52,295 | 25,210 |
| Research and development | 109,179 | 94,433 |
| General and administrative | 32,017 | 26,790 |
| Total operating expenses | 141,196 | 121,223 |
| Operating income (loss) | (88,901) | (96,013) |
| Interest income | 14,722 | 9,470 |
| Other income (expense) | (207) | (91) |
| Income tax expense (benefit) | (5,513) | (58) |
| Net income (loss) | (78,058) | (87,868) |
| Earnings per share, basic USD per share | (2.36) | (2.36) |
| Earnings per share, diluted USD per share | (2.36) | (2.36) |
| Weighted average shares, basic thousands of shares | 33,028 | 37,251 |
| Weighted average shares, diluted thousands of shares | 33,028 | 37,251 |
Balance sheet
CSVFiscal years (MGX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 27,386 | 41,722 |
| Marketable securities | 220,921 | 119,077 |
| Accounts receivable | 1,100 | 305 |
| Prepaid and other current assets | 8,396 | 4,434 |
| Total current assets | 257,960 | 165,538 |
| Property and equipment, net | 17,740 | 12,288 |
| Right-of-use asset | 39,917 | 35,094 |
| Total assets | 324,599 | 221,103 |
| Accounts payable | 533 | 1,489 |
| Total current liabilities | 37,309 | 22,933 |
| Lease liability, non-current | 40,186 | 34,632 |
| Total liabilities | 89,742 | 62,507 |
| Accumulated deficit | (223,002) | (310,870) |
| Total stockholders' equity | 234,857 | 158,596 |
| Total liabilities and equity | 324,599 | 221,103 |
| Common shares outstanding (cover page) thousands of shares | 37,383 | 37,621 |
Cash flows
CSVFiscal years (MGX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (78,058) | (87,868) |
| Stock-based compensation | 16,204 | 11,853 |
| Net cash from operating activities | (109,073) | (88,892) |
| Purchases of property and equipment | 3,114 | 574 |
| Net cash from investing activities | (88,157) | 103,529 |
| Net cash from financing activities | 84,013 | (356) |
| Net change in cash | (113,217) | 14,281 |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Metagenomi Therapeutics | 39,028 | not reported | (19,513)* | 37.8M | 6.2 quarters | 10-QJun 30, 2026 |
| Fitlife Brands | 1,089 | not reported | 3,635* | 9.4M | — | 10-QJun 30, 2026 |
| Immucell | 8,860 | 7,186 | 3,019* | 9.1M | — | 10-QJun 30, 2026 |
| Cue Biopharma | 17,392 | 7,877 | (29,004)* | 7.3M | 0.6 quarters | 10-QJun 30, 2026 |
| Avalo Therapeutics | 64,988 | not reported | (11,541)* | 57.8M | 23.9 quarters | 10-QSep 30, 2026 |
| Precision Biosciences | 81,698 | 0 | (15,132)* | 27.9M | 6.1 quarters | 10-QSep 30, 2026 |
| Opus Genetics | 88,812 | 755 | (11,950)* | 83.2M | 7.4 quarters | 10-QJun 30, 2026 |
| Acumen Pharmaceuticals | 53,075 | not reported | (26,653)* | 72.3M | 3.4 quarters | 10-QSep 30, 2026 |
| iBio | 56,395 | 0* | (6,228)* | 64.3M | 14.1 quarters | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.